PriceTargets.com logo

GRI Bio - GRI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $115.50
  • Forecasted Upside: 5,400.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.10 As of 05/2/2025 05:00 PM ET
▲ +0.15 (7.69%)

This chart shows the closing price for GRI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$2.10Closing price on 05/03/25:
Get New GRI Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRI

Analyst Price Target is $115.50
▲ +5,400.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for GRI Bio in the last 3 months. The average price target is $115.50, with a high forecast of $221.00 and a low forecast of $10.00. The average price target represents a 5,400.00% upside from the last price of $2.10.

This chart shows the closing price for GRI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
5/247/2410/241/255/255/26$0.29$55$111$166$221Closing price on 05/03/25: $2.10High$221.00Average$115.50Low$10.00




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in GRI Bio.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
12/9/2024HC WainwrightInitiated CoverageBuy$170.00
12/5/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$204.00 ➝ $221.00
10/8/2024Ascendiant Capital MarketsInitiated CoverageBuy$204.00
(Data available from 5/4/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2025
  • 1 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2025

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
GRI Bio logo
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Read More

Today's Range

Now: $2.10
Low: $1.88
High: $2.43

50 Day Range

MA: $3.98
Low: $1.21
High: $8.27

52 Week Range

Now: $2.10
Low: $1.10
High: $106.04

Volume

742,210 shs

Average Volume

280,902 shs

Market Capitalization

$1.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of GRI Bio?

The following Wall Street analysts have issued reports on GRI Bio in the last twelve months: Ascendiant Capital Markets, and HC Wainwright.
View the latest analyst ratings for GRI.

What is the current price target for GRI Bio?

0 Wall Street analysts have set twelve-month price targets for GRI Bio in the last year. Their average twelve-month price target is $115.50, suggesting a possible upside of 5,400.0%. Ascendiant Capital Markets has the highest price target set, predicting GRI will reach $221.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for GRI Bio in the next year.
View the latest price targets for GRI.

What is the current consensus analyst rating for GRI Bio?

GRI Bio currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRI will outperform the market and that investors should add to their positions of GRI Bio.
View the latest ratings for GRI.

What other companies compete with GRI Bio?

Other companies that are similar to GRI Bio include InMed Pharmaceuticals, Conduit Pharmaceuticals, Virax Biolabs Group, Kazia Therapeutics and Galecto. Learn More about companies similar to GRI Bio.

How do I contact GRI Bio's investor relations team?

GRI Bio's physical mailing address is TWO LOGAN SQUARE 100 N. 18TH STREET SUITE 300, PHILADELPHIA PA, 19103. The company's listed phone number is 267-607-8255 and its investor relations email address is vallon@jtcir.com. The official website for GRI Bio is www.vallon-pharma.com. Learn More about contacing GRI Bio investor relations.